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I
atrogenic hypoglycemia is a problem for people
affected by diabetes (1). It causes recurrent morbid-
ity in most people with type 1 diabetes and many
with advanced type 2 diabetes, and it is sometimes
fatal. It generally precludes maintenance of euglycemia
over a lifetime of diabetes and thus full realization of the
vascular beneﬁts of glycemic control. And, it compromises
defenses against subsequent falling plasma glucose con-
centrations and therefore causes a vicious cycle of recur-
rent hypoglycemia.
Hypoglycemia in diabetes is fundamentally iatrogenic,
the result of therapeutic hyperinsulinemia caused by treat-
ment with a sulfonylurea, a glinide, or insulin. But because
of the effectiveness of the normal glucose counterregu-
latory mechanisms, hypoglycemia is typically the result
of the interplay of therapeutic hyperinsulinemia and
compromised physiological and behavioral defenses
against falling plasma glucose concentrations in people
with diabetes (1).
The compromised physiological defenses include loss of
the normal decrements in insulin, increments in glucagon,
and increments in epinephrine as glucose levels fall in
absolute endogenous insulin deﬁcient diabetes (1). Loss of
decrements in insulin and of increments in glucagon
develop early in people with type 1 diabetes but only later
in people with type 2 diabetes. In view of increasing
evidence that -cell insulin secretion normally restrains
-cell glucagon secretion (2) and that a decrease in insulin
normally signals an increase in glucagon secretion during
hypoglycemia (3), loss of both the insulin and the glucagon
responses is plausibly attributable to -cell failure (1).
That construct ﬁts nicely with the fact that iatrogenic
hypoglycemia becomes a major problem early in people
with type 1 diabetes but only later in people with type 2
diabetes (1). Given the evidence that insulin also acts on
the hypothalamus to restrain glucagon secretion, there
may also be a central nervous system component to the
loss of the glucagon response (4). However, that cannot be
the sole explanation since the denervated (transplanted)
human pancreas and the denervated dog pancreas (as well
as the perfused pancreas and perifused islets) release
glucagon in response to low glucose concentrations in the
absence of innervation (1). In any event, people with
absolute endogenous insulin deﬁcient diabetes are largely
dependent on epinephrine for defense against falling glu-
cose levels. However, the increments in epinephrine are
often attenuated. That is a critical component of the
pathophysiology of glucose counterregulation in diabetes.
In the setting of absent insulin and glucagon responses,
attenuated increments in epinephrine cause the clinical
syndrome of defective glucose counterregulation with a
25-fold or greater increased risk of severe hypoglycemia
(1). Attenuated increments in sympathoadrenal, largely
sympathetic neural, activation cause the clinical syndrome
of hypoglycemia unawareness with a sixfold increased
risk of severe hypoglycemia (1).
The concept of hypoglycemia-associated autonomic fail-
ure (HAAF) in diabetes posits that recent antecedent
iatrogenic hypoglycemia (as well as sleep or prior exer-
cise) causes both defective glucose counterregulation (by
reducing the epinephrine response to subsequent hypogly-
cemia in the setting of absent insulin and glucagon re-
sponses) and hypoglycemia unawareness (by reducing the
sympathoadrenal response to subsequent hypoglycemia)
and thus a vicious cycle of recurrent hypoglycemia (1).
Perhaps the most compelling evidence for the clinical
impact of HAAF is the fact that hypoglycemia unaware-
ness and to some extent the attenuated epinephrine
component of defective glucose counterregulation are
reversed after as little as 2–3 weeks of scrupulous avoid-
ance of hypoglycemia in most affected subjects (5–8).
The mechanism(s) of the attenuated central nervous
system-mediated sympathoadrenal response to falling glu-
cose levels, the key feature of HAAF in type 1 diabetes and
advanced type 2 diabetes, is not known (1). Much of the
relevant investigative focus has been on the hypothalamus
and its environs in experimental animals (e.g., ref. 9).
However, recent studies in humans have raised the possi-
bility that a cerebral network, operating through the
thalamus, may be involved in the pathogenesis of HAAF
(10–12).
The current clinical approach to minimizing the risk of
iatrogenic hypoglycemia includes 1) acknowledging the
problem in subjects at risk, 2) applying the principles of
aggressive glycemic therapy, and 3) addressing the risk
factors for hypoglycemia (1). With respect to the latter, a
history of hypoglycemia unawareness should prompt a 2-
to 3-week period of scrupulous avoidance of hypoglycemia
with the anticipation that awareness will return (1,5–8).
Given the vascular beneﬁts of glycemic control, mean
glycemia as close to the nondiabetic range as can be safely
maintained is generally in the best interest of people with
diabetes (1). During effective therapy with lifestyle
changes or with glucose-lowering drugs other than a
sulfonylurea, a glinide, or insulin, the glycemic goal might
be a normal A1C. But such therapies are seldom effective
over a lifetime of diabetes. During therapy with a sulfonyl-
urea, a glinide, or insulin, the glycemic goal might be an
A1C 7%. The latter can sometimes be safely achieved
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diabetes, but it is often not possible later. Nonetheless,
despite increasing management efforts and expense as
insulin secretion declines and the glucose-lowering regi-
men required to maintain tight glycemic control becomes
increasingly complex slowly in type 2 diabetes and rapidly
in type 1 diabetes, hypoglycemia and its associated mor-
bidity becomes more frequent and sometimes fatal. Recent
estimates suggest that 6–10% of individuals with type 1
diabetes die from hypoglycemia (1). Increased mortality
has been reported during more aggressive glucose–lower-
ing therapy compared with less aggressive glucose–lower-
ing therapy in individuals with type 2 diabetes (13), in
those with hyperglycemia in intensive care units (14), and
in individuals with type 2 diabetes and A1C levels in the
lower and higher deciles (15). That excess mortality may
or may not be the direct result of iatrogenic hypoglycemia,
but some aspect of aggressive glycemic therapy must be
responsible. In addition, there are long-term beneﬁts from
reducing A1C from higher to lower—albeit still above
recommended—levels (16). Perhaps, therefore, a reason-
able glycemic goal is the lowest A1C that does not cause
severe hypoglycemia (that which requires the assistance
of another person), preserves awareness of hypoglycemia,
and causes an acceptable number of documented episodes
of symptomatic hypoglycemia at a given stage in the
evolution of the individual’s diabetes. Ultimately, glucose
levels that are low enough to prevent symptoms of hyper-
glycemia become a reasonable goal in individuals with
limited life expectancy or functional capacity in whom
glycemic control is unlikely to be beneﬁcial.
Clearly, the current clinical approach is inadequate in
most individuals with type 1 diabetes and many with
advanced type 2 diabetes. Iatrogenic hypoglycemia re-
mains the limiting factor in the glycemic management of
their diabetes (1). How then, apart from sacriﬁcing glyce-
mic goals completely, will hypoglycemia be eliminated
from the lives of all people affected by diabetes in the
future (Figure 1)?
Prevention and cure of diabetes will eliminate iatrogenic
hypoglycemia, but no one knows when those goals will be
accomplished. The development of successful plasma glu-
cose regulated insulin replacement or secretion will al-
most assuredly eliminate iatrogenic hypoglycemia (17).
These therapeutic regimens are coming, probably closed-
loop insulin replacement (18) before islet transplantation
(19). But some of us have been saying that these regimens
are coming for decades. We don’t know when either will
become available to appreciable numbers of people with
diabetes. Pending these major developments, we should
seek to reverse compromised glucose counterregulatory
defenses to at least minimize the risk of iatrogenic hypo-
glycemia. As discussed in the following paragraphs, sev-
eral potential clinical approaches have been probed in
humans. However, none have been shown to be both
effective and safe in suitably powered randomized con-
trolled trials.
Parenteral administration of glucagon is commonly used
to treat iatrogenic hypoglycemia in diabetes (20); its
infusion could be used to prevent hypoglycemia (21). Oral
and parenteral amino acids stimulate glucagon secretion,
and oral alanine has been shown to prevent nocturnal
hypoglycemia in type 1 diabetes (22–24). Similarly, oral
administration of the epinephrine simulating 2-adrenergic
agonist terbutaline has been shown to prevent nocturnal
hypoglycemia in type 1 diabetes (22–24). Apart from its
use as a component of a closed-loop system (21), the use
of glucagon, amino acids, or terbutaline to minimize the
risk of hypoglycemia suffers from the fact that their
glucose-raising actions are not plasma glucose-regulated.
Nonetheless, their judicial application could prove beneﬁ-
cial if it were documented in randomized controlled trials.
Among other possibilities, adenosine antagonists, such
as caffeine, raise catecholamine levels and enhance symp-
toms of hypoglycemia in people with diabetes (25,26).
Modaﬁnil, a drug that decreases extracellular -aminobu-
tyric acid levels, increases symptoms of hypoglycemia
(27). Fructose infusion, thought to increase glucokinase
activity, increases the epinephrine and glucagon responses
to hypoglycemia in nondiabetic individuals (28). Ventro-
medial hypothalamic microinjection of the nonselective
KATP channel agonist (opener) diazoxide enhances epi-
nephrine and glucagon responses to hypoglycemia in a rat
model of HAAF (29), and systemic administration of a
selective Kir6.2/SUR-1 KATP channel agonist enhances the
epinephrine response to hypoglycemia in nondiabetic and
diabetic rats (30). However, oral diazoxide suppresses the
glucagon response and has no effect on the epinephrine
response to hypoglycemia in humans (31). Although ven-
tromedial hypothalamic glutamate release is thought to
mediate the sympathoadrenal response to hypoglycemia in
rats (32), antagonism of glutamate signaling with the
N-methyl-D-aspartate (NMDA) receptor antagonist meman-
tine (33) or with the amino-3-hydroxy-5-methy1–4-isoazol
propionate (AMPA) receptor antagonist caroverine (34)
does not decrease sympathoadrenal responses to, or
symptoms of, hypoglycemia in nondiabetic individuals.
Three potential approaches to reversing compromised
glucose counterregulatory defects—adrenergic antago-
nists, a selective serotonin reuptake inhibitor, and an
opiate antagonist—are of particular interest because they
enhance counterregulatory responses to falling glucose
levels, i.e., the responses are plasma glucose-regulated,
and they prevent the key feature of HAAF. Combined -
and -adrenergic blockade with the -adrenergic antago-
nist phentolamine and the -adrenergic antagonist pro-
pranolol prevents the effect of hypoglycemia to attenuate
the sympathoadrenal response to subsequent hypoglyce-
mia, the key feature of HAAF, in nondiabetic individuals
(35). Selective serotonin reuptake inhibitors increase the
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rats, sertraline both enhances the epinephrine response to
hypoglycemia and prevents the attenuated epinephrine
response to hypoglycemia in diabetic animals (37). In
humans, oral ﬂuoxetine enhances the plasma epinephrine
and muscle sympathetic nerve activity responses to hypo-
glycemia in both nondiabetic and diabetic individuals (36).
Infusion of the -opiate antagonist naloxone increases the
response to hypoglycemia in humans (38). Administration
of naloxone during hypoglycemia prevents the effect of
hypoglycemia to attenuate the epinephrine response to
hypoglycemia the following day in nondiabetic individuals
(39) and individuals with type 1 diabetes (40).
In this issue of Diabetes, Poplawski et al. (41) report
their novel approach to dissection of the hypothalamic
alterations in HAAF. They used quantitative PCR to iden-
tify a series of mouse ventromedial hypothalamic genes
that were induced by insulin-induced hypoglycemia. They
then found that a subset of those genes did not respond to
hypoglycemia following four episodes of recurrent hypo-
glycemia but did respond to hypoglycemia if naloxone
(which prevents HAAF in humans [39,40]) was adminis-
tered during each episode of prior recurrent hypoglyce-
mia. Those genes included those that regulate pyruvate
dehydrogenase kinase isoenzyme 4, glycerol 3-phosphate
dehydrogenase 1, angiopoietin-like 4, and cyclin-depen-
dent kinase inhibitor 1a (p21). In addition, carnitine palmi-
toyltransferase 1A was inhibited after recurrent hypo-
glycemia, and that was prevented by naloxone. The
authors provide an admittedly speculative but nonetheless
provocative metabolic interpretation of their data. Unfor-
tunately, the effects of recurrent hypoglycemia were not
shown to be associated with the key feature of HAAF, an
attenuated epinephrine response to hypoglycemia, and the
impact of naloxone on gene responses to a single episode
of hypoglycemia was not assessed. Clearly, however, the
generic approach of Poplawski et al. could be used both to
further explore the mechanisms of the effect of naloxone
and to explore the mechanisms of the various other
interventions mentioned earlier.
Pending the prevention and cure of diabetes or the
development of plasma glucose-regulated insulin replace-
ment or secretion that might eliminate hypoglycemia from
the lives of all people affected by diabetes, the potential
exists to minimize the risk of iatrogenic hypoglycemia by
reversing the compromised physiological and behavioral
defenses against falling plasma glucose concentrations
that characterize type 1 diabetes and advanced type 2
diabetes. Several approaches that have been probed in
humans are summarized in this article. It would seem that
people with diabetes would be served if these or other
approaches were subjected to suitably powered random-
ized controlled trials.
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